Deal or Case news
NautaDutilh assisted NewAmsterdam with their underwritten offering of ordinary shares and pre-funded warrants on Nasdaq.

The ordinary shares were offered at a price of USD 19 per share and the pre-funded warrants at a price of USD 18,9999 per pre-funded warrant. With full exercise of the over-allotment option on closing, the offering results in gross proceeds for NewAmsterdam of approximately USD 200 million.

It has been an absolute delight working alongside Covington & Burling LLP in this transaction, together assisting NewAmsterdam with yet another major offering following their successful de-SPAC transaction in 2022
Paul van der Bijl, Corporate M&A partner

Next to Paul and Nina Kielman (lead tax partner) the team consisted of Marloes van der Laan, Eline van Marle, Joppe Schoute and Daan Hagelstein.

About NewAmsterdam
NewAmsterdam (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to provide transformational therapies for patients suffering from a range of diseases where abnormal cholesterol metabolism remains a significant cause of morbidity and mortality despite treatment with existing standards of care. They are developing safe, convenient, oral metabolic therapies to help change the treatment paradigm for these patients.

Cookie notification

This functionality uses third-party cookies. Change your cookie preferences to view this content or view more information.
These cookies ensure that the website works properly. These cookies cannot be disabled.
These cookies can be placed by third parties, such as YouTube or Vimeo.
By deactivating categories, it is possible that related functionalities within the website may no longer work properly. It is always possible to change your preferences at a later time. View more information.